Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Antwerp, Belgium.
Parasitol Res. 2019 Oct;118(10):2743-2752. doi: 10.1007/s00436-019-06443-2. Epub 2019 Aug 31.
Leishmaniasis is a neglected parasitic disease for which the current antileishmania therapeutics are hampered by drug toxicity, high cost, need for parenteral administration, increasing treatment failure rates, and emergence of drug resistance. The R&D pipeline had run fairly dry for several years, but fortunately some new drug candidates are now under (pre)clinical development. Identification of novel drugs will nevertheless remain essential to adequately sustain and improve effective disease control in the future. In this review, a package of standard and accessible R&D approaches is discussed with expansion to some alternative strategies focusing on parasite-host and vector-host interactions.
利什曼病是一种被忽视的寄生虫病，目前的抗利什曼病疗法受到药物毒性、高成本、需要注射、治疗失败率上升和耐药性出现的阻碍。研发管道已经干涸了好几年，但幸运的是，现在有一些新的药物候选物正在进行（临床前）临床开发。然而，为了在未来充分维持和改善有效的疾病控制，确定新的药物仍将是至关重要的。在这篇综述中，讨论了一整套标准和可及的研发方法，并扩展到一些侧重于寄生虫-宿主和媒介-宿主相互作用的替代策略。
